Program Overview

Some cancer treatments may cause damage to your heart or put you at risk for heart disease. At the Ross Heart Hospital, our goal is to lessen or eliminate that risk as you complete your cancer treatments.

Our multidisciplinary team includes specialists from Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the Ohio State Heart and Vascular Center who come together to provide care for heart failure through services like electrophysiology and cardiac imaging.

Our Approach

By working together, our physicians at the OSUCCC – James and the Ross Heart Hospital created a holistic approach to caring for patients with cancer before, during and after treatments that improves the patient’s quality of life.

Our program combines exercise, calming activities and other therapies to address heart-related issues that sometimes result from cancer treatments. The cardio therapies are personalized for each patient, and promote improved physical and mental health.

The key to a patient’s success is collaboration among oncologists, cardiologists and patients.


Over the past two decades, powerful immunotherapy drugs that work to alter a patient’s immune system have proven effective in fighting cancer. During the same period, however, doctors have seen an increase in patients experiencing cardiovascular problems.

Ibrutinib is a targeted oral therapy that has transformed the treatment of chronic lymphocytic leukemia so that this disease can be more effectively managed. The drug has also shown tremendous promise for many other cancers. However, some patients treated with this revolutionary therapy develop cardiovascular side effects, including abnormal and dangerous heart rhythms.

Daniel Addison, MD, co-director of the Cardio-Oncology program at the Ohio State Wexner Medical Center, is leading a study called Early Detection and Mechanisms of Novel Cancer Immunotherapy Associated With Cardio-Toxicity. The study will identify people who are at higher risk for heart problems related to ibrutinib. It will also use heart imaging and blood tests to identify early markers of heart damage and develop treatment strategies for patients with signs of heart damage related to ibrutinib use.

The goal of the clinical trial is to develop a customizable strategy in treating patients and possibly apply these techniques to other new cancer immunotherapy drugs.

Share this Page

Our Leaders

Ragavendra Baliga, MBBS

Co-director, Cardio-oncology Program

Daniel Addison

Daniel Addison, MD

Co-director, Cardio-oncology Program

Interests: Cardiac imaging and heart rhythm disorders from cancer treatments
Yvonne Efebera

Yvonne Efebera, MD

Interests: Amyloid
Garrie Haas

Garrie Haas, MD

Interests: Chemotherapy-induced cardiomyopathy
Ray Hershberger

Ray Hershberger, MD

Interests: Genetics in chemotherapy-induced caridomyopathy

Raul Weiss, MD

Interests: Rhythm disorders associated with cancer chemotherapy
Rami Kahwash

Rami Kawash, MD

Interests: Amyloid
Bhavana Konda

Bhavana Konda, MD, MPH

Interests: Hypertension in patients with oncology drugs, particularly tyrosine kinase inhibitors
Maryam Lustberg

Maryam Lustberg, MD

Oncology Lead

Viren Patel, MD

Interests: Hypertension in patients with oncology drugs, particularly tyrosine kinase inhibitors
Sakima Smith

Sakima Smith, MD

Interests: Cardio-oncology
Ajay Vallakati

Ajay Vallakati, MBBS

Interests: Chemotherapy-induced cardiomyopathy and pulmonary hypertension with chemotherapy
Sumithira Vasu

Sumithira Vasu, MBBS

Interests: Challenges of managing orthostatic hypotension after BMT

Raul Weiss, MD

Interests: Rhythm disorders associated with cancer chemotherapy